Dermavant Sciences Ltd.

General Information
Business:

 

We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. We have a robust medical dermatology pipeline with both late-stage and early-development product candidates. Our pipeline targets specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 0
Founded: 2015
Contact Information
Address Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom
Phone Number +44 (117) 918-1293
Web Address http://www.dermavant.com
View Prospectus: Dermavant Sciences Ltd.
Financial Information
Market Cap $319.0mil
Revenues $0 mil (last 12 months)
Net Income $-255.3 mil (last 12 months)
IPO Profile
Symbol DRMT
Exchange NASDAQ
Shares (millions): 7.7
Price range $12.00 - $14.00
Est. $ Volume $100.1 mil
Manager / Joint Managers Jefferies/ SVB Leerink/ Guggenheim Securities
CO-Managers -
Expected To Trade: 6/20/2019
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change